Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics at baseline

From: Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study

  Total population
  n = 250
Demographics  
Age, years 52 ± 13
Female, no. (%) 197 (79)
DMARD therapy  
Prior DMARDs (no.) 3.4 ± 1.6
Methotrexate use, no. (%) 199 (80)
Methotrexate dose (mg/wk) 23 (15 to 25)
Prednisone use, no. (%) 82 (33%)
Prednisone dose (mg/day) 7.5 (5 to 10)
Disease status  
Disease duration (years) 8 (4 to 17)
Rheumatoid factor positive, no. (%) 179 (72)
Erosive disease, no. (%) 194 (78)
Erythrocyte sedimentation rate (mm/h) 30 ± 23
C-reactive protein (mg/dl) 11 (5 to 24)
DAS28 5.2 ± 1.2
  1. Mean values ± SD, median and interquartile range, or percentages are shown.
  2. DAS28, Disease Activity Score in 28 joints; DMARD, diseases modifying anti rheumatic drug.